Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2Sarcoma 1Gynecologic 1Breast 1

Conditions

Melanoma 117Carcinoma, Non-Small-Cell Lung 102Carcinoma, Renal Cell 69Colorectal Neoplasms 46Neoplasm Metastasis 41Squamous Cell Carcinoma of Head and Neck 39Carcinoma, Hepatocellular 38Neoplasms 36Lung Neoplasms 34Stomach Neoplasms 33Urinary Bladder Neoplasms 22Carcinoma, Transitional Cell 21Hodgkin Disease 20Brain Neoplasms 20Pancreatic Neoplasms 18Ovarian Neoplasms 18Prostatic Neoplasms 17Head and Neck Neoplasms 16Colonic Neoplasms 16Skin Neoplasms 15Triple Negative Breast Neoplasms 14Sarcoma 14Glioblastoma 14Adenocarcinoma Of Esophagus 14Carcinoma, Merkel Cell 13Small Cell Lung Carcinoma 12Rectal Neoplasms 12Esophageal Neoplasms 12Breast Neoplasms 12Uveal Melanoma 11

Interventions

trametinib 5dabrafenib 5pembrolizumab 3lenvatinib 3cobimetinib 2cemiplimab 2atezolizumab 2Vemurafenib 2Radiotherapy, Intensity-Modulated 2Paclitaxel 2Nivolumab 2zimberelimab 1selpercatinib 1fludarabine 1cabozantinib 1aldesleukin 1abemaciclib 1Taxes 1Ipilimumab 1Immunoglobulin G 1Disulfides 1Cyclophosphamide 1CTLA-4 Antigen 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × Nivolumab × 1 year × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05696548 2026-04-09

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

National Cancer Center Hospital East

Phase 2 Active not recruiting
51 enrolled
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡